AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17277001 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of ibandronate
Number of subjects: 0
Study 15145173 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy single fraction (SF)
Number of subjects: 0
Study 15145173 — intervention group
Group type: COMPARATOR
Intervention: 24 Gy in multiple fractions (MF)
Number of subjects: 0
Study 15145173 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment overall
Number of subjects: 0
Study 11267717 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Number of subjects: 25
Study 11267717 — intervention group
Group type: COMPARATOR
Intervention: Endocervical lavage
Number of subjects: 25
Study 9677173 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually focused counselling and skills training intervention including written materials
Number of subjects: 492
Study 9677173 — intervention group
Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 492
Study 9677173 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic procedure
Number of subjects: 492
Study 8021734 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 daily 2-hour infusions of 100 mg/m2
Number of subjects: 94
Study 8021734 — intervention group
Group type: COMPARATOR
Intervention: 8 daily 75-minute infusions of 62.5 mg/m2
Number of subjects: 94
Study 2595106 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg over 20 min, followed by 0.9 mg/kg/h)
Number of subjects: 7
Study 2595106 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 micrograms/kg over 20 min, followed by 3 micrograms/kg/h)
Number of subjects: 7
Study 2595106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 7
Study 2595106 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline and Salbutamol
Number of subjects: 7
Study 4402080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (20 mg.)
Number of subjects: 0
Study 4402080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (40 mg.)
Number of subjects: 0
Study 4402080 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (10 mg.)
Number of subjects: 0
Study 4402080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31356374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG group)
Number of subjects: 59
Study 31356374 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (NEO group)
Number of subjects: 59
Study 31647087 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily red wine vinegar ingestion for 8 weeks
Number of subjects: 45
Study 31647087 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose (30 mW, 10 J/cm2, 9 s per point, 810 nm)
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose (100 mW, 40 J/cm2, 11 s per point, 810 nm)
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose + Gluma Desensitizer
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose + Gluma Desensitizer
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1.0 W, 10 Hz, 100 mJ, 1064 nm)
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser + Gluma Desensitizer
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose + Nd:YAG laser
Number of subjects: 32
Study 28391435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose + Nd:YAG laser
Number of subjects: 32
Study 26333366 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF combined with IC BMC therapy
Number of subjects: 60
Study 26333366 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF
Number of subjects: 60
Study 26333366 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF and IC serum
Number of subjects: 60
Study 26333366 — intervention group
Group type: COMPARATOR
Intervention: Peripheral placebo (saline)
Number of subjects: 60
Study 24032424 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 10(6) fibroblasts per linear cm of erosion margin
Number of subjects: 11
Study 24032424 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study 21876298 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-therapy combined with progressive limb loading
Number of subjects: 61
Study 21876298 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 61
Study 19478489 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment (PT) during pregnancy
Number of subjects: 83
Study 19478489 — intervention group
Group type: COMPARATOR
Intervention: Dental examination for periodontitis (Control group A)
Number of subjects: 83
Study 16937393 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 16937393 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 16937393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15051841 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (<10% energy as carbohydrate)
Number of subjects: 15
Study 15051841 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (<30% energy as fat)
Number of subjects: 15
Study 12182772 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, external beam radiotherapy, and carmustine (BCNU)
Number of subjects: 270
Study 12182772 — intervention group
Group type: COMPARATOR
Intervention: Surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine (BCNU)
Number of subjects: 270
Study 9440482 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.1 IU/kg daily
Number of subjects: 8
Study 9440482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 25 mg morning and evening
Number of subjects: 8
Study 9440482 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) plus Prednisolone
Number of subjects: 8
Study 7975785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. (n = 25)
Number of subjects: 50
Study 7975785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d. (n = 25)
Number of subjects: 50
Study 2642689 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (TV)
Number of subjects: 248
Study 2642689 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy and drainage (SV)
Number of subjects: 248
Study 2642689 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 248
Study 1108355 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival depot corticosteroid
Number of subjects: 89
Study 1108355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 30466545 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + CET
Number of subjects: 102
Study 30466545 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 102
Study 28433211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine monotherapy (KM) 1 mg/kg i.v. (with up to three additional doses of 0.5 mg/kg each)
Number of subjects: 183
Study 28433211 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of ketamine and propofol (CoKP) 0.5 mg/kg each i.v. (with up to three additional doses of 0.25 mg/kg each)
Number of subjects: 183
Study 28433211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine monotherapy (KM)
Number of subjects: 183
Study 28433211 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of ketamine and propofol (CoKP)
Number of subjects: 183
Study 26054140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion at 'Xiasanhuang', once a day, with an interval of 2 days after every 10 treatments for 2 months.
Number of subjects: 106
Study 26054140 — intervention group
Group type: COMPARATOR
Intervention: Benazepril hydrochloride, 5 to 10 mg orally, once a day for 2 months.
Number of subjects: 106
Study 23478471 — intervention group
Group type: EXPERIMENTAL
Intervention: SAND (n = 6)
Number of subjects: 12
Study 23478471 — intervention group
Group type: COMPARATOR
Intervention: GRASS (n = 6)
Number of subjects: 12
Study 20545545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen bone allograft
Number of subjects: 0
Study 20545545 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone (native maxilla)
Number of subjects: 0
Study 19734172 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG)
Number of subjects: 80
Study 17409109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol at a dose of 10-20 mg/day (mean dose: 16 +/- 4 mg/day) for a mean of 12 +/- 1 months
Number of subjects: 30
Study 17409109 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study 15747470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil 200 mg bid over a 5 day period followed by 5 days of placebo
Number of subjects: 1042
Study 15747470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil 200 mg bid over a 10 day period
Number of subjects: 1042
Study 11723020 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with CK-MB measurement
Number of subjects: 496
Study 11723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increased CK-MB levels after CABG
Number of subjects: 496
Study 11723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CK-MB levels
Number of subjects: 496
Study 9006357 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 14
Study 9006357 — intervention group
Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 14
Study 9006357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hearing loss > 50 dB
Number of subjects: 14
Study 9006357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hearing loss < 50 dB
Number of subjects: 14
Study 8322791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose OKT3 (5 mg)
Number of subjects: 50
Study 8322791 — intervention group
Group type: COMPARATOR
Intervention: Low-dose OKT3 (2 mg)
Number of subjects: 50
Study 8322791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 3521443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus amiloride (25 mg hydrochlorothiazide + 2.5 mg amiloride)
Number of subjects: 40
Study 3521443 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone (25 mg)
Number of subjects: 40
Study 29617633 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 225
Study 29617633 — intervention group
Group type: COMPARATOR
Intervention: Group General Health Education (GHE)
Number of subjects: 225
Study 29617633 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 225
Study 29617633 — intervention group
Group type: COMPARATOR
Intervention: Group GHE
Number of subjects: 225
Study 27381741 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicompeting risks analysis
Number of subjects: 1419
Study 27381741 — intervention group
Group type: COMPARATOR
Intervention: Composite endpoints (CEP) analysis
Number of subjects: 1419
Study 27381741 — intervention group
Group type: COMPARATOR
Intervention: Univariate analyses for each component endpoint
Number of subjects: 1419
Study 24188732 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management educational intervention
Number of subjects: 183
Study 24188732 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 183
Study 22570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related adverse effects (specifically constipation, emesis, and confusion)
Number of subjects: 402
Study 22570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with two adverse effects
Number of subjects: 402
Study 22570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with three adverse effects
Number of subjects: 402
Study 22570188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with four adverse effects
Number of subjects: 402
Study 20467286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 898
Study 18086314 — intervention group
Group type: EXPERIMENTAL
Intervention: SR stimulation coordination training group (SCT)
Number of subjects: 30
Study 18086314 — intervention group
Group type: COMPARATOR
Intervention: Conventional coordination training group (CCT)
Number of subjects: 30
Study 18086314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15857741 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acustimulation wrist band
Number of subjects: 96
Study 15857741 — intervention group
Group type: COMPARATOR
Intervention: Sham acustimulation wrist band
Number of subjects: 96
Study 15857741 — intervention group
Group type: COMPARATOR
Intervention: No acustimulation
Number of subjects: 96
Study 12147960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid lowering strategy
Number of subjects: 0
Study 12147960 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid lowering strategy
Number of subjects: 0
Study 12147960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose warfarin
Number of subjects: 0
Study 12147960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12147960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid strategy
Number of subjects: 0
Study 10440141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (40 patients; mean dose = 190 +/- 43 mg/day)
Number of subjects: 85
Study 10440141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (45 patients; mean dose = 176 +/- 32 mg/day)
Number of subjects: 85
Study 10440141 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 85
Study 10440141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 7558391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) using washed spermatozoa
Number of subjects: 50
Study 7558391 — intervention group
Group type: COMPARATOR
Intervention: LH-timed natural intercourse
Number of subjects: 50
Study 1599636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg felodipine plus 5 mg enalapril
Number of subjects: 36
Study 1599636 — intervention group
Group type: COMPARATOR
Intervention: 10 mg felodipine
Number of subjects: 36
Study 1599636 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 36
Study 3863470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 40
Study 3863470 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine-clobazam
Number of subjects: 40
Study 31039482 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation for 12 weeks
Number of subjects: 181
Study 31039482 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 181
Study 30378274 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of hyperosmolar rectal lubricant daily for 7 days
Number of subjects: 60
Study 30378274 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral TDF/FTC for 7 days
Number of subjects: 60
Study 30378274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hyperosmolar lubricant and daily oral TDF/FTC for 7 days
Number of subjects: 60
Study 27687377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 2.5mg/min
Number of subjects: 90
Study 27687377 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 30μg/min
Number of subjects: 90
Study 26198931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 97
Study 26198931 — intervention group
Group type: COMPARATOR
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97
Study 23714672 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation combined with transcatheter arterial chemoembolization (RFA + TACE)
Number of subjects: 62
Study 23714672 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation alone (RFA)
Number of subjects: 62
Study 20301014 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanols (1 to 20 mg/day)
Number of subjects: 0
Study 18371559 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 564
Study 18371559 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomization syncope
Number of subjects: 564
Study 18371559 — intervention group
Group type: COMPARATOR
Intervention: Syncope versus non-syncope patients
Number of subjects: 564
Study 16634903 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT), 2 treatments, 2 weeks apart
Number of subjects: 36
Study 16634903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 16634903 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT)
Number of subjects: 36
Study 12477710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 12
Study 12477710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11037786 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697 (co-artemether) - 4 x 4 tablets over 48 hours
Number of subjects: 179
Study 11037786 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine - 4 tablets initially, followed by two tablets each at 6-8, 24, and 48 hours
Number of subjects: 179
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with alpha‐fetoprotein > or = 20 micrograms/L
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography screening
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort screening
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up screening
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Men only follow-up screening
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality from hepatocellular carcinoma
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha‐fetoprotein > 20 micrograms/L
Number of subjects: 1069
Study 7543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1069
Study 2795032 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgen sprinkled around the reduced hip joint after arthroplasty
Number of subjects: 76
Study 2795032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Colgen)
Number of subjects: 76
Study 626810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglycamide infusion at a rate of 4 mg per kg per min for one hour
Number of subjects: 15
Study 626810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioglycamide infusion
Number of subjects: 15
Study 31294137 — intervention group
Group type: EXPERIMENTAL
Intervention: KBMSI-2 (6 g twice per day for 8 weeks)
Number of subjects: 0
Study 31294137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28722299 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB) surgery, N=15
Number of subjects: 745
Study 28722299 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle and medical intervention (ILMI), N=17
Number of subjects: 745
Study 26562602 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-treatment outcomes (abstinence and good clinical outcome during treatment)
Number of subjects: 0
Study 26562602 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses based on good clinical outcome, level of drinking during treatment, age at onset of alcohol dependence, and feeling more energetic
Number of subjects: 0
Study 23274619 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic single-use laryngoscope blades
Number of subjects: 1863
Study 23274619 — intervention group
Group type: COMPARATOR
Intervention: Metallic reusable laryngoscope blades
Number of subjects: 1863
Study 23274619 — intervention group
Group type: COMPARATOR
Intervention: Metallic single-use laryngoscope blades
Number of subjects: 1863
Study 21469973 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 2 mg / Estradiol 1 mg (DRSP/E2)
Number of subjects: 244
Study 21469973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 18341665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 543
Study 18341665 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 543
Study 16502051 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel and povidine iodine lavage
Number of subjects: 80
Study 16502051 — intervention group
Group type: COMPARATOR
Intervention: Cephtriaxon and lavage
Number of subjects: 80
Study 16502051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 12685672 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 0
Study 12685672 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional medical treatments)
Number of subjects: 0
Study 10752744 — intervention group
Group type: EXPERIMENTAL
Intervention: AT(H) concentrate infusions every 8 hours to raise plasma level to 175% in the first 72 hours after injury
Number of subjects: 9
Study 10752744 — intervention group
Group type: EXPERIMENTAL
Intervention: AT(H) concentrate infusions
Number of subjects: 9
Study 10752744 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 9
Study 9373047 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-enriched water (1000 mg CO2/kg)
Number of subjects: 24
Study 9373047 — intervention group
Group type: COMPARATOR
Intervention: Fresh water
Number of subjects: 24